TY - UNPB
T1 - Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation
T2 - a longitudinal observational study
AU - Cysique, Lucette A.
AU - Jakabek, David
AU - Bracken, Sophia G.
AU - Allen-Davidian, Yasmin
AU - Heng, Benjamin
AU - Chow, Sharron
AU - Dehhaghi, Mona
AU - Pires, Ananda Staats
AU - Darley, David R.
AU - Byrne, Anthony
AU - Phetsouphanh, Chansavath
AU - Kelleher, Anthony
AU - Dore, Gregory J.
AU - Matthews, Gail V.
AU - Guillemin, Gilles J.
AU - Brew, Bruce J.
PY - 2022/6/7
Y1 - 2022/6/7
N2 - Cognitive impairment and function post-acute mild to moderate COVID-19 are poorly understood. We report findings of 128 prospectively studied SARS-CoV-2 positive patients. Cognition and olfaction were assessed at 2-, 4- and 12-months post-diagnosis. Lung function, physical and mental health were assessed at 2-month post diagnosis. Blood cytokines, neuro-biomarkers, and kynurenine pathway (KP) metabolites were measured at 2-, 4-, 8- and 12- months. Mild to moderate cognitive impairment (demographically corrected) was present in 16%, 23%, and 26%, at 2-, 4- and 12-months post diagnosis, respectively. Overall cognitive performance mildly, but significantly (p<.001) declined. Cognitive impairment was more common in those with anosmia (p=.05), but only at 2 months. KP metabolites quinolinic acid, 3-hydroxyanthranilic acid, and kynurenine were significantly (p<.001) associated with cognitive decline. The KP as a unique biomarker offers a potential therapeutic target for COVID-19-related cognitive impairment.
AB - Cognitive impairment and function post-acute mild to moderate COVID-19 are poorly understood. We report findings of 128 prospectively studied SARS-CoV-2 positive patients. Cognition and olfaction were assessed at 2-, 4- and 12-months post-diagnosis. Lung function, physical and mental health were assessed at 2-month post diagnosis. Blood cytokines, neuro-biomarkers, and kynurenine pathway (KP) metabolites were measured at 2-, 4-, 8- and 12- months. Mild to moderate cognitive impairment (demographically corrected) was present in 16%, 23%, and 26%, at 2-, 4- and 12-months post diagnosis, respectively. Overall cognitive performance mildly, but significantly (p<.001) declined. Cognitive impairment was more common in those with anosmia (p=.05), but only at 2 months. KP metabolites quinolinic acid, 3-hydroxyanthranilic acid, and kynurenine were significantly (p<.001) associated with cognitive decline. The KP as a unique biomarker offers a potential therapeutic target for COVID-19-related cognitive impairment.
U2 - 10.1101/2022.06.07.22276020
DO - 10.1101/2022.06.07.22276020
M3 - Preprint
T3 - medRxiv
BT - Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation
ER -